MENU × BUSINESS
Banking And InsuranceCryptocurrencyDigital MarketingErpFood And BeveragesHealthcareLegalMarketing And AdvertisingMedia And EntertainmentMetals And MiningOil And GasRetailTelecom
TECHNOLOGY
Artificial IntelligenceBig DataCloudCyber SecurityE CommerceEducationGaming And VfxIT ServiceMobileNetworkingSAPScience And TechnologySecuritySoftwareStorage
PLATFORM
CiscoDatabaseGoogleIBMJuniperM2MMicrosoftOracleOracleRed Hat
LEADERSHIP
CEO ReviewCompany Review
MAGAZINE
ASIA INDIA
STARTUPS CLIENT SPEAK CONTACT US

The Silicon Review Asia

Aurobindo Pharma Seeks to Add A Couple of Branded Products Acrotech Biopharma’s Portfolio

Aurobindo Pharma Seeks to Add A Couple of Branded Products Acrotech Biopharma’s Portfolio

Hyderabad based pharmaceutical manufacturing company, Aurobindo Pharma Limited, has been a bit slow on the acquisition front. It had made some key acquisitions in the past and is now considering to add a few branded products to its subsidiary, Acrotech Biopharma’s portfolio. After acquiring a portfolio of seven oncology injectable products from US-based Spectrum Pharmaceuticals Inc for $300 million, Acrotech Biopharma hopes to generate a revenue of around $100 million from it for the initial year after the completion of the transaction for Aurobindo.

At the Q3FY19 results conference call, N Govindarajan, Managing Director of Aurobindo Pharma, said that they keep evaluating their domestic business sometimes, but now they are prioritising to integrate what they have acquired. This could take time and therefore, they will just stick to adding a couple of branded products into the portfolio instead of making any large acquisition. He also said that Aurobindo Pharma will be overseeing the dietary supplements segment in India in the long-term as well as file approvals for at least two biosimilar products in 2020.“Subsequent year we should get approval as far as Europe is concerned as approval time is around 210-days if everything is in line in terms of the filing. As far as US is concerned, you should estimate around 12 to 18 months for approval from the date of filing”, he added.

Aurobindo Pharma hopes to commercialise its product in the Chinese market after two and a half years. Presently, it has received the permits for building its facility, set to be completed within a year.

YOU MAY ALSO LIKE

Tariff plans will cost higher from the next financial year as telecom companies are gearing up to increase rates

The ongoing Covid pandemic had significantly increased the number of mobile and internet users worldwide. The high amount of usage is expected to drop...

Business Travelers to Stay at Singapore’s Changi Airport Bubble

Singapore’s open economy depends heavily on tourism and business. But its vibrant but small economy has been hurting as the circumstances due to...

Countries in Asia-Pacific are marching towards ‘green recovery’ amidst Covid-19 crisis

2020 has been an unforgettable year for many of us. The ongoing Covid crisis has reminded people that it is very important to have an uninterrupted an...

Department of Telecommunication to announce the new schedule for 5G trials

Department of Telecommunications (DoT) is all set to announce the new schedule for 5G trials. The Dot made this decision after being pulled by the par...

RECOMMENDED